Product nameAnti-EpCAM antibody [VU-1D9] (Biotin)
See all EpCAM primary antibodies
DescriptionMouse monoclonal [VU-1D9] to EpCAM (Biotin)
SpecificityWe have data to indicate that this antibody may not cross react with Rat. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
Tested applicationsSuitable for: IHC-P, Flow Cyt, ICC/IFmore details
Species reactivityReacts with: Human
Small cell lung carcinoma cells
- Human breast carcinoma tissue.
This product was changed from ascites to tissue culture supernatant on 29th September 2017 and product received after this date will be from tissue culture supernatant.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 0.41% PBS, 0.05% BSA
Concentration information loading...
PurityProtein G purified
Light chain typekappa
- Anti-EpCAM antibody [VU-1D9] (FITC) (ab112067)
- Anti-EpCAM antibody [VU-1D9] (Phycoerythrin) (ab112068)
- Anti-EpCAM antibody [VU-1D9] (PerCP/Cy5.5®) (ab157319)
- Anti-EpCAM antibody [VU-1D9] (ab187372)
- Anti-EpCAM antibody [VU-1D9] - BSA and Azide free (ab212579)
- Anti-EpCAM antibody [VU-1D9] (Alexa Fluor® 647) (ab239273)
- Anti-EpCAM antibody [VU-1D9] (Allophycocyanin) (ab239288)
Our Abpromise guarantee covers the use of ab79079 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||Use a concentration of 1 - 2 µg/ml. Perform enzymatic antigen retrieval before commencing with IHC staining protocol.
Incubate for 30 min at RT. Staining of formalin/paraffin tissues requires digestion of tissue sections with pepsin at 1mg/ml Tris-HCl, pH 2.0 for 15 min at RT or 10 min at 37°C.
|Flow Cyt||Use at an assay dependent concentration.
5ul per test per one million cells
|ICC/IF||Use at an assay dependent concentration.|
FunctionMay act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Tissue specificityHighly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.
Involvement in diseaseDefects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
Sequence similaritiesBelongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Cellular localizationLateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction.
- Information by UniProt
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
This product has been referenced in:
- Casavant BP et al. Efficient sample preparation from complex biological samples using a sliding lid for immobilized droplet extractions. Anal Chem 86:6355-62 (2014). Read more (PubMed: 24927449) »
- Berry SM et al. Purification of cell subpopulations via immiscible filtration assisted by surface tension (IFAST). Biomed Microdevices 13:1033-42 (2011). Read more (PubMed: 21796389) »